Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in…
STRIDE regimen of a single priming dose of tremelimumab added to Imfinzi is the first dual immune checkpoint blockade regimen to improve overall survival in a Phase III trial in…
Read More...
Read More...
